GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (OTCPK:MLLCF) » Definitions » Interest Paid

MLLCF (Molecular Partners AG) Interest Paid


View and export this data going back to 2018. Start your Free Trial

What is Molecular Partners AG Interest Paid?

Interest Paid only applicable to companies reporting Cash Flow from Operations in direct method.


Molecular Partners AG Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.